London Insider News

London’s Chancery Lane is home to one of the Square Mile’s most distinctive and characterful drinking establishments, celebrating ten years of operation this January. The Pregnant Man is a finalist for the Best Bar gong at the Toast the City Awards, a recognition that speaks to its enduring appeal among City workers and creatives alike. Part owned by Saatchi and Saatchi, the bar originally operated as an agency-only pub in a car park before opening its doors fully to the public on Chancery Lane. The bar takes its name from one of Saatchi and Saatchi’s most celebrated advertising campaigns from The post The Pregnant Man Bar Marks A Decade With A Toast The City Awards Nomination appeared first on London Insider News.

Bristol Myers Squibb (BMY) and Ono Pharmaceutical have filed a lawsuit against Amgen (AMGN) in Delaware federal court to block a proposed biosimilar of their cancer drug Opdivo. The suit, filed last week and made public on Monday, alleges that Amgen’s biosimilar candidate would infringe seven U.S. patents covering the blockbuster immunotherapy. Bristol Myers and Ono are asking the court to block all sales of the Amgen biosimilar while those patents remain in force. Opdivo, which is also known by its scientific name nivolumab, has been approved in the U.S. to treat advanced or metastatic cancers including melanoma, non-small cell The post Bristol Myers Squibb And Ono Pharmaceutical Sue Amgen (AMGN) To Block Opdivo Biosimilar appeared first on London Insider News.

Pharmaceutical manufacturers continue to face significant challenges understanding what affiliated fees actually buy within pharmacy benefit manager contracting structures. A Federal Trade Commission settlement with Express Scripts, announced on February 4, 2026, required major business practice changes, including transparency reforms and reshoring the Ascent group purchasing organisation. Despite the settlement moving one PBM aggregator onshore, manufacturers still lack contract-level clarity on the compensation flowing through affiliated entities. Rebate aggregators and affiliated contracting entities can sit between manufacturers and PBMs while receiving compensation that is extremely difficult to evaluate at the contract level. Industry consultants argue that if a fee is The post FTC Settlement Forces PBM Transparency But Manufacturers Still Face Opaque Fee Structures appeared first on London Insider News.

The Department of Justice has made diagnosis coding practices in the Medicare Advantage risk adjustment space a top enforcement priority, with settlements mounting across the industry. The latest resolution involves a $14.1 million settlement with Complete Health Partners Holdings, LLC to resolve allegations that it caused the submission of false diagnosis codes in violation of the False Claims Act. The underlying case, United States ex rel. Bowers v. Complete Health Partners, Inc., et al., was brought under the qui tam provisions of the FCA by a former employee of two Medicare Advantage Organisation co-defendants. The government contends that Complete Health The post Four FCA Settlements Signal Intensifying DOJ Crackdown On Medicare Advantage Diagnosis Coding Programs appeared first on London Insider News.

The iShares UK Dividend ETF (LSE: IUKD) has become an increasingly attractive vehicle for investors seeking broad UK income exposure across blue-chip stocks. For every £100 invested in the fund, £8.46 is allocated to just two of its most prominent holdings: Lloyds Banking Group and Legal & General. Legal & General currently holds the largest dividend yield in the FTSE 100 at 7.4%, making it one of the most sought-after income stocks among retail investors in the UK. Lloyds, meanwhile, benefits from strong retail familiarity, with many investors holding current accounts or mortgages with the bank before ever buying its The post iShares UK Dividend ETF (IUKD) Allocates Over 8% To Lloyds (LLOY) And Legal & General (LGEN) Shares appeared first on London Insider News.